Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management.


Journal

ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 29 09 2023
revised: 05 01 2024
accepted: 15 01 2024
pmc-release: 05 02 2025
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

Human gut microbiota are recognized as critical players in both metabolic disease and drug metabolism. However, medication-microbiota interactions in cardiometabolic diseases are not well understood. To gain a comprehensive understanding of how medication intake impacts the gut microbiota, we investigated the association of microbial structure with the use of single or multiple medications in a cohort of 134 middle-aged adults diagnosed with cardiometabolic disease, recruited from Alberta's Tomorrow Project. Predominant cardiometabolic prescription medication classes (12 total) were included in our analysis. Multivariate Association with Linear Model (

Identifiants

pubmed: 38665607
doi: 10.1021/acsptsci.3c00261
pmc: PMC11040554
doi:

Types de publication

Journal Article

Langues

eng

Pagination

991-1001

Informations de copyright

© 2024 The Authors. Published by American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Auteurs

Jane Shearer (J)

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
Faculty of Kinesiology, University of Calgary, Calgary, Alberta T2N 1N4, Canada.

Shrushti Shah (S)

Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
Faculty of Kinesiology, University of Calgary, Calgary, Alberta T2N 1N4, Canada.

Grace Shen-Tu (G)

Alberta's Tomorrow Project, Cancer Control Alberta, Alberta Health Services, Calgary, Alberta T2T 5C7, Canada.

Kristina Schlicht (K)

Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel 24105, Germany.

Matthias Laudes (M)

Institute of Diabetes and Clinical Metabolic Research, University Medical Center Schleswig-Holstein, Kiel 24105, Germany.
Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.

Chunlong Mu (C)

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta T2N 1N4, Canada.

Classifications MeSH